



# Pentosan Polysulfate Inhibits Attachment and Infection by SARS-CoV-2 In Vitro: Insights into Structural Requirements for Binding

Sabrina Bertini<sup>1,\*</sup> Anna Alekseeva<sup>2,\*</sup> Stefano Elli<sup>1,\*</sup> Isabel Pagani<sup>3,\*</sup> Serena Zanzoni<sup>4,\*</sup>  
Giorgio Eisele<sup>2</sup> Ravi Krishnan<sup>5</sup> Klaus P. Maag<sup>6</sup> Christian Reiter<sup>5</sup> Dominik Lenhart<sup>6</sup> Rudolf Gruber<sup>6</sup>  
Edwin A Yates<sup>7,\*</sup> Elisa Vicenzi<sup>3,\*</sup> Annamaria Naggi<sup>1,\*\*</sup> Antonella Bisio<sup>1,\*\*</sup> Marco Guerrini<sup>1,\*\*</sup>

<sup>1</sup>Istituto di Ricerche Chimiche e Biochimiche G. Ronzoni, Milan, Italy

<sup>2</sup>Centro Alta Tecnologia "Istituto di Ricerche Chimiche e Biochimiche G. Ronzoni" Srl, Milan, Italy

<sup>3</sup>Viral Pathogenesis and Biosafety Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

<sup>4</sup>Centro Piattaforme Tecnologiche, University of Verona, Verona, Italy

<sup>5</sup>Paradigm Biopharmaceuticals Ltd., Melbourne, Victoria, Australia

<sup>6</sup>Bene PharmaChem GmbH & Co.KG, Geretsried, Germany

<sup>7</sup>Department of Biochemistry and Systems Biology, ISMIB, University of Liverpool, Liverpool, United Kingdom

Address for correspondence Marco Guerrini, Istituto di Ricerche Chimiche e Biochimiche, "G. Ronzoni," Milan 20133, Italy (e-mail: guerrini@ronzoni.it).

Thromb Haemost 2022;122:984–997.

## Abstract

Two years since the outbreak of the novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic, there remain few clinically effective drugs to complement vaccines. One is the anticoagulant, heparin, which in 2004 was found able to inhibit invasion of SARS-CoV (CoV-1) and which has been employed during the current pandemic to prevent thromboembolic complications and moderate potentially damaging inflammation. Heparin has also been shown experimentally to inhibit SARS-CoV-2 attachment and infection in susceptible cells. At high therapeutic doses however, heparin increases the risk of bleeding and prolonged use can cause heparin-induced thrombocytopenia, a serious side effect. One alternative, with structural similarities to heparin, is the plant-derived, semi-synthetic polysaccharide, pentosan polysulfate (PPS). PPS is an established drug for the oral treatment of interstitial cystitis, is well-tolerated, and exhibits weaker anticoagulant effects than heparin. In an established Vero cell model, PPS and its fractions of varying molecular weights inhibited invasion by SARS-CoV-2. Intact PPS and its size-defined fractions were characterized by molecular weight distribution and chemical structure using nuclear magnetic resonance spectroscopy and liquid chromatography–mass spectrometry, then employed to explore the structural basis of interactions with SARS-CoV-2 spike

## Keywords

- ▶ pentosan polysulfate
- ▶ SARS-CoV-2
- ▶ COVID-19
- ▶ antiviral agent

\* *Joint first authors.*

\*\* *Senior authors.*

received

January 3, 2021

accepted

March 3, 2022

published online

March 23, 2022

DOI <https://doi.org/10.1055/a-1807-0168>.

ISSN 0340-6245.

© 2022. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)

Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

protein receptor-binding domain (S1 RBD) and the inhibition of Vero cell invasion. PPS was as effective as unfractionated heparin, but more effective in inhibiting cell infection than low-molecular-weight heparin (on a weight/volume basis). Isothermal titration calorimetry and viral plaque-forming assays demonstrated size-dependent binding to S1 RBD and inhibition of Vero cell invasion, suggesting the potential application of PPS as a novel inhibitor of SARS-CoV-2 infection.

## Introduction

The enveloped, positive sense RNA virus, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), belonging to the *Coronaviridae*, is responsible for the coronavirus disease 2019 (COVID-19) pandemic and causes serious clinical morbidities that are consistent with the onset of SARS.<sup>1</sup> By late 2021, the total number of COVID-19 deaths worldwide stood at over 5 million, but this is probably an underestimate owing to the difficulties of collecting accurate data globally. Despite the significant contribution of vaccines to preventing much severe morbidity and mortality caused by SARS-CoV-2 infection, there remains an urgent need to develop additional drugs to treat or prevent the infection. COVID-19 is a disease which continues to occur due to the waning of immunity, the infection of immunosuppressed patients, or those with underlying illness, as well as the emergence of mutations and the resulting breakthrough infections. Several drugs, marketed for other therapeutic indications, have been re-purposed to treat COVID-19 patients and antiviral strategies that include treatment with remdesivir or convalescent plasma have received emergency approval.<sup>2,3</sup> Despite promising results, the use of such treatments is limited, owing to their expense and, because they can only be delivered intravenously. Additional treatments are therefore required and, indeed, during the writing of this article, the first orally available antiviral drug against COVID, molnupiravir, was approved for use in the United Kingdom.<sup>4,5</sup>

One existing family of drugs which have been re-purposed for treatment of COVID-19 is heparins. Heparins are a class of polydisperse, linear, sulfated polysaccharides of animal origin. Besides their well-known anticoagulant properties, heparins have been shown to inhibit cell invasion by SARS CoV-2,<sup>6,7</sup> SARS CoV-1,<sup>8,9</sup> influenza H5N1,<sup>10</sup> as well as several flaviviruses, including Dengue and Yellow Fever viruses.<sup>11</sup> Heparin can also influence the ability of the infected cell to survive, as evinced by a study of the survival of cells infected by Zika virus.<sup>12</sup> The activity of heparin against SARS-CoV-2 has been established using several *in vitro* experimental models and its efficacy appears to depend largely on its interactions with the spike protein 1 receptor binding domain (S1-RBD).<sup>6,7,13</sup>


Regarding the clinical use of heparin, a systematic review and meta-analysis of the association of anticoagulant status and mortality in COVID-19 patients was conducted encompassing 29 articles that had been published before January 2021. The study concluded that both therapeutic and

prophylactic anticoagulant regimes reduced in-hospital mortality compared with untreated patients.<sup>14</sup> Anticoagulant therapy has been recommended in the prophylaxis of thromboembolism in COVID patients with respiratory infection and reduced mobility.<sup>15</sup> Nevertheless, the occurrence of bleeding complications and the documented risk of heparin-induced thrombocytopenia (HIT) after prolonged exposure both limit the use of heparin in patients having high incidence of venous thromboembolism, particularly for high-dose administration.

The proposed mechanism of inhibition by heparin involves competition for the binding of the SARS-CoV-2 spike protein (S1) with endogenous cell-surface heparan sulfate (HS), a co-receptor which serves as an anchor, and to facilitate the conformational change that enables viral binding to angiotensin-converting enzyme 2 (ACE2).<sup>6,7</sup> The high negative charge density of heparin, a close structural analogue of HS, favors interaction with predominantly positively charged amino acid residues of S1 (R346, R355, N354, R357, K444, and R466).<sup>6,16</sup> The results from several studies have suggested that other sulfated molecules and highly charged polyelectrolytes could also provide potential targets for the design of inhibitors against the entry of viruses.<sup>17,18</sup>

Pentosan polysulfate (PPS) is a chemically sulfated derivative of pentosan, a plant-derived xylan that has been approved for the treatment of bladder pain and discomfort in interstitial cystitis ([ema.europa.eu/en/medicines/human/EPAR/elmiron](http://ema.europa.eu/en/medicines/human/EPAR/elmiron)) and could represent an alternative to heparin. PPS is produced by the exhaustive chemical O-sulfation of hardwood glucuronoxylan whose backbone comprises a linear polymer of D-xylopyranose (Xyl) units linked  $\beta$  (1–4) to each other and branched with 4-O-methyl-D-glucuronic acid (MGA) residues linked  $\alpha$  (1–2) to the xylose backbone<sup>19</sup> (**Fig. 1A**). PPS has poor anticoagulant activity and is known for its anti-inflammatory activities and affinity for the cytokines, interleukin (IL)-4, IL-5 and IL-13, resulting in similar anti-inflammatory efficacy to topical steroids in a guinea pig model of allergic rhinitis, following intranasal administration.<sup>20</sup> Indeed, aerosol administration could be an attractive approach for upper airway drug treatments, thereby enabling the relatively low bioavailability of PPS after oral administration<sup>21–23</sup> to be overcome.

In the present study, a sample of PPS (API) was fractionated according to its charge density and molecular dimension using anion exchange chromatography. The parent polysaccharide and six fractions were characterized in terms of their molecular weight distribution, as well as by nuclear



**Fig. 1** (A) Major structural signatures of PPS. MGA: branching 4-O-methyl-2,3-di-O-sulfated glucuronic acid, Ac: acetyl group. (B) Low-field and high-field proton NMR spectral regions of PPS and its fractions. PPS, pentosan polysulfate.

magnetic resonance (NMR) spectroscopy and liquid chromatography–mass spectrometry (LC-MS) analysis. These were all then evaluated for their ability to bind the S1-RBD and to inhibit virus invasion in comparison with both unfractionated heparin (UFH) and its low molecular-weight-heparin (LMWH) counterpart. The reduced anticoagulant potency of PPS and its fractions compared with heparin, alongside its well-tolerated oral administration even at high dose (300 mg daily),<sup>24</sup> suggests that oral administration or, even better, aerosol administration of PPS might provide an effective and safe prophylactic treatment of COVID-19 disease.

## Methods

### Preparation of PPS Fractions

Native PPS (Bene PharmaChem GmbH, Germany) was fractionated on a DEAE Sephacel column applying aqueous NaCl (0.6–2.0 M, stepwise elution) as eluent. PPS fractions were precipitated by the addition of a twofold excess of ethanol and storing at  $-30^{\circ}\text{C}$  overnight. Samples were collected by centrifugation (3,500 rpm, 10 minutes), washed with 70% ethanol, and dried in vacuo at  $40^{\circ}\text{C}$ .

### NMR Characterization of PPS and PPS Fractions

$^1\text{H-NMR}$  and heteronuclear single quantum coherence (HSQC) NMR spectra were acquired using a Bruker Avance 500 NEO instrument (Bruker, Karlsruhe, Germany), equipped with 5 mm cryoprobe. Ca. 40 mg of samples were weighed and dissolved in 0.5 mL of deuterated phosphate buffer solution (PBS), 0.15 mM, pH 7.1. Proton spectra were recorded at 303 K, with presaturation of solvent during relaxation delay. Recording and integration of quantitative HSQC spectra as well as quantification of the monosaccharide building blocks were performed according to the published study.<sup>19</sup>

### Molecular Weight of PPS and PPS Fractions

The molecular weight distributions of PPS and PPS-derived fractions were performed on a Viscotek 305 HPLC system (Viscotek, Houston, United States) equipped with a triple-detector array exploiting simultaneous application of refraction index (RI) detector, viscometer and right-angle laser light-scattering (RALLS), employing an adaptation of the published method.<sup>25,26</sup> The applied RI increment ( $dn/dc$ ) was found to be 0.093 mL/g and was used to convert the RI response to concentration.<sup>19</sup>

### LC-MS Characterization of PPS and PPS Fractions

Analyses by LC-MS of unfractionated PPS and its fractions were performed by ion pair reversed phase chromatography coupled with high-resolution mass spectrometry as previously described.<sup>19</sup> Briefly, the separation of PPS oligomers was achieved on a HPLC 1100 (Agilent, Santa Clara, United States) system equipped with a high-resolution ESI-FTICR mass spectrometer Solarix 7T (Bruker Daltonics, Billerica, Massachusetts, United States), using a Kinetex 2.6 $\mu$ m C18 column (100  $\times$  2.1 mm I.D., Phenomenex, Torrance, California, United States) and dibutylamine acetate as ion pairing agent (eluent A and B containing 10 mM DBA and 10 mM acetic acid in water and methanol, respectively). All reagents were of LC-MS grade. The separation was achieved using a multistep gradient at 0.1 mL/min flow rate: the solvent composition was held at 35% B for the first 3 minutes, then increased to 55% B over 2 minutes, and to 75% B over another 35 minutes, where it was held at 75% for 20 minutes; afterwards, the content of eluent B was increased to 98% in 30 minutes, where it was held for 10 minutes to elute the longest components. Finally, it was returned to 35% B over 2 minutes, and held for the last 23 minutes for equilibrating the chromatographic column before the next run. The following ESI-MS (electrospray ionization mass spectrometry) parameters were used: capillary voltage, 3.2 kV; nebulizer gas pressure, 1 bar; drying gas, 3.7 mL/min, and 180 $^{\circ}$  C. The mass spectra acquisition was performed in  $m/z$  200 to 3,000 range with time domain 1M and ion source accumulation of 300 milliseconds. Injection volume was 3  $\mu$ L for both 5 mg/mL unfractionated PPS and 2.5 mg/mL fractions. The fraction, Fr.2.0M, was not analyzed by LC-MS due to poor chromatographic separation and the poor ionization of high-molecular-weight oligosaccharides, which results in low MS sensitivity.

### Dynamic Light Scattering

Dynamic light scattering (DLS) experiments were performed using a Zetasizer Nano ZS instrument (Malvern Panalytical, Malvern, United Kingdom) operating at 633 nm with backscatter detection at 173 $^{\circ}$ . The protein solution (2  $\mu$ M) was allowed to equilibrate with or without the addition of salt at the measurement temperature of 25  $^{\circ}$ C before starting acquisition. To analyze the S1-RBD/PPS complex size, the solutions were obtained by mixing S1-RBD with unfractionated and fractionated PPS solutions in 20 mM HEPES buffer with salt at different protein ligand molar ratios. The complexes were transferred to a disposable cell at room temperature and analyzed 2 minutes post-mixing. Data were analyzed using Zetasizer software version 7.11 (Malvern Panalytical, Malvern, United Kingdom) and each value corresponds to the average of three separate measurements.

### Circular Dichroism

Circular dichroism (CD) spectra data were collected at 25 $^{\circ}$ C on a Jasco J-1500 instrument (JASCO, Great Dunmow, United Kingdom) equipped with a Peltier unit-controlled cell holder. The spectra in the far-ultraviolet (far-UV) region

(200–250 nm) were recorded using a quartz cell (Hellma, Southend-on-Sea, United Kingdom) with a path length of 0.1 cm, a response time of 1 second, a scan speed of 20 nm/min, and bandwidth of 0.5 nm, and each spectrum was the average of five scans. To address the conformational state of the S1-RBD domain in HEPES buffer, CD data were acquired on S1-RBD (4–10  $\mu$ M) samples just after reconstitution with de-ionized water as a control and after buffer exchange (HEPES buffer, pH 7.4 with NaCl 200 mM). To analyze the conformational changes upon PPS complex formation, the S1-RBD solutions were incubated with unfractionated and fractionated PPS solutions in HEPES buffer at different protein ligand molar ratios and CD spectra were recorded immediately.

### Isothermal Titration Calorimetry

Isothermal titration calorimetry (ITC) was used to characterize the binding affinities between PPS fractions and the S1-RBD domain. The experiments were performed at 25 $^{\circ}$ C using a MicroCal PEAQ-ITC (Malvern Ltd., Malvern, United Kingdom). Both protein and ligand were prepared in PBS or HEPES buffer pH 7.2. Briefly, SARS-CoV-2-RBD protein (Sino Biological, China) was first reconstituted with MilliQ filtered water and then, to remove the excess of trehalose, the buffer was exchanged with PBS or 20 mM HEPES pH 7.2, NaCl 60 mM using an Amicon Ultra concentrator (10 kDa filter, 0.5 mL). Each lyophilized PPS fraction was initially resuspended with 500  $\mu$ L of the same buffer. The protein and ligand stock solutions were then diluted to different concentrations for ITC analysis with PPS or HEPES buffer and 140 or 200 mM salt. For all the experiments, S1-RBD was taken in the cell (2–3  $\mu$ M) and PPS fractions in the syringe (30  $\mu$ M). Each ITC experiment consisted of 20 injections of 2  $\mu$ L each with an initial delay of 180 seconds between injections, and a stirring rate of 500 rpm. To estimate the thermodynamic parameters ( $K_D$ ,  $\Delta H$ , and  $\Delta S$ ), the data were fitted using the MicroCal analysis software.

### Vero Cell Culture and Assays

Vero cells were plated at  $2.5 \times 10^5$  cells/well in 24-well plates in EMEM supplemented with 10% fetal bovine serum (complete medium). Twenty-four hours later, three different PPS protocol treatments were adopted:

- **Cell treatment:** Cells were incubated with serial dilutions of PPS in 250  $\mu$ L of complete medium for 30 minutes and then 50  $\mu$ L of supernatant containing 50 plaque-forming units (PFU) of SARS-CoV-2 isolate (GISAID accession ID: EPI\_ISL\_413489) were added.<sup>6</sup>
- **Virus treatment:** 50 PFU of SARS-CoV-2 in 50  $\mu$ L of complete medium were incubated with compound serial dilutions of PPS for 30 minutes at 37 $^{\circ}$ C and then added to Vero cells in a final volume of 300  $\mu$ L.
- **Cell + virus treatment:** 50 PFU of SARS-CoV-2 in 50  $\mu$ L of complete medium were incubated with compound serial dilutions and cells were incubated with serial dilutions of PPS within the same range for 30 minutes at 37 $^{\circ}$ C in 250  $\mu$ L. After 30 minutes of incubation at 37 $^{\circ}$ C, the

virus-containing supernatant was added to the PPS-treated cells.

In all three PPS protocol treatments, the incubation was then extended for 1 hour at 37°C. Then, supernatants were discarded and 500 µL of 1% methylcellulose overlay dissolved in medium containing 1% of fetal bovine serum was added to each well. After 3 days, cells were fixed using a 6% (v/v) formaldehyde:phosphate-buffered saline solution and stained with 1% (w/v) crystal violet (Sigma-Aldrich, Italy) in 70% (v/v) methanol (Sigma-Aldrich, Italy). The plaques were counted under a stereoscopic microscope (SMZ-1500, Nikon).

### Statistical Analysis

Prism GraphPad software v. 9.0 (www.graphpad.com) was used for the statistical analyses. Comparison among groups was performed using the one-way analysis of variance (ANOVA). The mean of each treatment column was compared with the control column (Nil; no treatment) applying the Bonferroni correction. The symbol \*\*\*\* indicates a *p*-value <0.0001, \*\*\* indicates a *p*-value <0.001, and \*\* indicates a *p*-value <0.01.

### Coagulation Assays

All fractions were stored frozen (−20°C) at 1 mg/mL in Aqua-Dest. Heparin (A3004,0001, 196 IU/mg; Applichem, Darmstadt, Germany) and LMWH (enoxaparin, 100 mg/mL, Sanofi-Aventis, Frankfurt, Germany) were stored according to the manufacturer's instructions for use. Dilutions in human pool plasma were used with the following concentrations (first dilution step to 100 µg/mL in 0.9% NaCl) (*n* = 6): 0; 3.125; 6.25; 12.5; 25; and 50 µg/mL. The activated partial thromboplastin time (aPTT; SyntASil TM; reference range: 25–38 seconds) and anti-Xa activity (Liquid anti-Xa TM; reference range 0 IU/mL) were measured with commercially available assays according to the manufacturer's instructions (Werfen, Munich, Germany) and were analyzed on the ACL TOP analyzer (Werfen, Munich, Germany).

### PPS Structural Optimization and Molecular Docking Simulations of PPS-SARS-CoV-2 S1-RBD Domain

A model comprising the linear hexasaccharide portion of PPS was represented by the xylohexasaccharide: 2,3,4-trisulfo-Xyl-β(1–4)-[2,3-disulfo-Xyl]<sub>5</sub>-OH. Two limit conformations of this xylohexasaccharide, characterized by all 2,3-disulfo-Xyl residues in <sup>1</sup>C<sub>4</sub> or <sup>4</sup>C<sub>1</sub> conformations, were built. In each 2,3-disulfo-Xyl residue, the conformation of the sulfate groups was manually adjusted to reduce the steric hindrance considering their orientation as axial or equatorial corresponding to the <sup>1</sup>C<sub>4</sub> or <sup>4</sup>C<sub>1</sub> chairs. In both models, the φ<sub>*i*</sub>/ψ<sub>*i*</sub> glycosidic backbone conformation was also manually adjusted before the final energy minimization step, to reduce the steric hindrance of the glycan chain. The final conformations of these two xylohexasaccharides having Xyl residues in <sup>1</sup>C<sub>4</sub> and <sup>4</sup>C<sub>1</sub> were energy-minimized using the Maestro 12.7 Macromodel 13.1 software and molecular mechanic Amber\* force-field (Suite 2021–1, Schrödinger Inc. San Diego) (►Supplementary Fig. S5, available in the online version).

The nonbonded distance cut-offs were set as 20.0, 8.0, and 4.0 Å for electrostatic, Van der Waals, and hydrogen bond potential energy interactions, respectively. The minimization procedure involved 10,000 steps (default energy minimization algorithm) or a gradient threshold  $1.0 \times 10^{-3}$  KJ mol<sup>−1</sup> Å<sup>−1</sup>, before the docking stage. Only the xylohexasaccharides in <sup>1</sup>C<sub>4</sub> (see the Results section) was submitted to molecular docking.

The hexasaccharide was docked on the surface of the S1-RBD (PDB ID 6M0J) targeting the sequence of positively charged patches R346, R355, K356, R357, which present good accessibility when the S1-RBD is in the “up” conformation in the trimeric protein S (PDB ID 6VSB). All the hexasaccharide torsional degrees of freedom were adjusted during automatic docking, except for the glycosidic dihedrals φ<sub>*i*</sub>/ψ<sub>*i*</sub> (*i* = 1, 5), while the S1-RBD was set as rigid. The docking grid was set as *L<sub>x</sub>* = *L<sub>y</sub>* = 80, *L<sub>z</sub>* = 120 points, while the center of the grid was: (CM<sub>*x*</sub>, CM<sub>*y*</sub>, CM<sub>*z*</sub>) = (−40.272, 25.851, 21.266). The grid spacing was 0.375 Å (default). The software Autodock 4.2 was used for the automatic docking. The Lamarckian genetic algorithm 4.2 was used for the docking in combination with the following set of parameters: number of runs = 100, population size = 2,000, maximum number of energy evaluations =  $2.5 \times 10^7$ , maximum number of generations =  $2.7 \times 10^5$ . After the search procedure, the obtained poses of the ligand–receptor complex were clustered (tolerance root-mean-square deviation <2.0 Å) and each clusters characterized by the lowest binding energy (Autodock score function) and highest population (number of poses for cluster) were selected.

## Results

### Isolation and Structural Characterization of PPS Fractions

To correlate the structural properties of PPS with their ability to bind the spike protein and inhibit virus propagation, PPS was fractionated by anion exchange chromatography and fractions were characterized by light scattering, NMR and LC-MS.

The molecular weights of PPS and its fractions were obtained by size exclusion chromatography coupled with a triple detector array (HP-SEC-TDA), consisting of light scattering, refractive index, and viscometer, following a similar procedure to that adopted for UFH and LMWHs.<sup>25,26</sup> The advantage of this method compared with classical approaches is that it does not require column calibration with reference standards possessing the same chemical structure as the samples to be analyzed, nor do they need to exhibit well-defined molecular weight and narrow polydispersity. The accuracy of such relative measurements is therefore affected by the quality of the standards employed. The distinct elution times of PPS and its fractions reflects their different molecular weight and molecular weight distributions (►Supplementary Fig. S1, available in the online version). The *M<sub>w</sub>* (weight average molecular weight), *M<sub>n</sub>* (number average molecular weight), polydispersity *D* (expressed as *M<sub>w</sub>*/*M<sub>n</sub>*), *R<sub>h</sub>*, and η (dL/g) values obtained for the samples are reported in ►Table 1. The *M<sub>w</sub>* values of the

**Table 1** Properties of PPS and its fractions; the results refer to the mean values of duplicate injections

Sample	$M_w$ (kDa)	$M_n$ (kDa)	$D (M_w/M_n)$	$R_h^a$	$\eta^b$ (dL/g)
(PPS)	5.7	4.4	1.3	1.6	0.01
(Fr. 1.0M)	3.7	3.6	1.0	1.3	0.04
(Fr. 1.1M)	5.3	5.3	1.0	1.6	0.05
(Fr. 1.2M)	7.0	6.9	1.0	1.9	0.06
(Fr. 1.3M)	9.2	9.1	1.0	2.3	0.08
(Fr. 1.4M)	11.8	11.7	1.0	2.7	0.10
(Fr. 2.0M)	17.3	17.0	1.0	3.4	0.15

Abbreviation: PPS, pentosan polysulfate.

<sup>a</sup>Hydrodynamic radius.

<sup>b</sup>Intrinsic viscosity.

fractions ranged between 3.7 and 17.3 kDa, corresponding to an average chain length of 11 to 50 monosaccharide units.

PPS and its fractions, except for fraction Fr. 2.0M, with the highest molecular weight, were analyzed by LC-MS. The LC-MS profiles with the identified components are shown in **Fig. 2** with the  $m/z$  data and retention times of the components. Some additional minor structures identified are also reported in **Supplementary Fig. S2** (available in the online version). Overall, the fractions differ from each other principally in the length of oligosaccharides, whereas all the structural groups (e.g., sulfate groups, MGA, and acetyl moieties) identified in PPS are homogeneously distributed in each fraction, as confirmed by NMR analysis described below.


All the fractions contain linear O-sulfated oligomers  $Xyl_nS_{2n+1}$  with one unsubstituted hydroxyl group at C1 of the reducing end (RE) (**Fig. 1A**) as prevalent components (**Fig. 2**). Oligosaccharides with two unsubstituted hydroxyl groups ( $Xyl_nS_{2n}$ ) are detected only in trace amounts, confirming essentially the complete sulfation of the internal chains (**Supplementary Fig. S2**, available in the online version). Minor oligosaccharides with an additional 14 Da mass shift  $Xyl_nS_{2n+1}$  generally accompany the most abundant  $Xyl_nS_{2n+1}$  species and show multiple peaks in the LC-MS profile, most likely representing various positional isomers related to the presence of L-rhamnose instead of D-xylose.

For all fractions, ion exchange chromatography-based fractionation led to co-elution of regular  $Xyl_nS_{2n+1}$  oligosaccharides with minor dehydrated  $Xyl_nS_{2n+1}-H_2O$  oligomers, these latter formed by the loss of a water molecule from the RE, for  $Xyl_nS_{2n}-H_2O$ , containing a C2–C3 double bond at the RE (**Supplementary Table S1**, available in the online version). The co-elution of shorter dehydrated oligomers with  $Xyl_nS_{2n+1}$  suggests that the former is better retained by the ion exchange column, most likely because of their higher polarity. An inverse trend is observed for pyridine-containing oligomers. The  $Xyl_nS_{2n+1}Py$  envelope is slightly shifted to longer chains (**Fig. 2**) that may be explained by charge compensation between a negatively charged sulfate and positively charged nitrogen atom of a pyridine moiety

(**Fig. 1A**). Interestingly, MGA-branched structures, with or without 3-O-acetylation ( $Xyl_nMGA_1S_{2n+1}Ac_1$  and  $Xyl_nMGA_1S_{2n+2}$ , **Fig. 1A**), are also characterized by slightly longer chains than the regular  $Xyl_nS_{2n+1}$  oligomers. Their co-elution might be associated with weaker retention of MGA-branched structures on the anion exchange column due to steric effects. As previously reported, MGA-containing structures often exhibit multiple peaks of positional isomers.<sup>19</sup>

Qualitative and quantitative fingerprints of monosaccharide composition of PPS and its fractions were obtained by <sup>1</sup>H and HSQC-NMR spectroscopy, according to methods recently described (**Fig. 1B** and **Supplementary Table S1**, available in the online version).<sup>19</sup> The monosaccharide composition was determined by <sup>1</sup>H NMR (**Table 2**). The data provided quantitative information concerning some structural features of PPS which can be related directly to the xylan source (e.g., MGA content) and its preparation process, such as minor modifications at the RE of PPS chains (e.g., through formation of double bonds, pyridine derivatives, and possible methylation as well as residual acetylation). The RE signal of  $\alpha$ -xylose at 5.38 ppm decreases with the increase in molecular weight, in agreement with data obtained by HP-SEC-TDA and LC-MS.  $\Delta Xylred$  (CHO) was calculated from the integral of the H3 signal at 6.78 ppm, while the level of  $Xyl3Ac-2MGA$  was calculated from the acetyl signal at 2.31 ppm. Finally, the degree of acetylation was determined by calculating the ratio of the sum of acetyl groups between 2.35 and 2.1 ppm and the sum of xylose-related signals.

The advantage of the quantitative 2D-NMR method<sup>27,28</sup> consists of the enhancement of signal dispersion compared with the mono-dimensional spectra, which enables better resolution of additional minor signals of PPS. The molar percentages of each residue (**Supplementary Table S1**, available in the online version) were calculated from the abundance of corresponding cross-peak volumes normalized to the sum of all the cross-peak volumes.<sup>19</sup> Both mono- and bidimensional techniques indicated the structural similarity of all PPS fractions, which differ mainly by the quantity of their reducing and non-reducing residues (**Table 2** and **Supplementary Table S1** [available in the online version]).




**Fig. 2** TIC profiles of PPS and PPS fractions with the identified components. Xyl: xylose repeating unit, MGA: branching 4-O-methyl-glucuronic acid, S: sulfate group, Ac: acetyl group, Py: pyridine moiety. PPS, pentosan polysulfate; TIC, total ion current.

**Table 2** Monosaccharide compositional analysis by  $^1\text{H}$  NMR (molar percentage)

Residue	PPS	Fr. 1.0M	Fr. 1.1M	Fr. 1.2M	Fr. 1.3M	Fr. 1.4M	Fr. 2.0M
Xyl + XylNR	67.5	68.9	73.6	75.5	76.4	76.9	82.4
Xyla	5.0	4.7	2.6	2.0	1.5	1.3	1.0
Xyl3Ac-2MGA	2.3	2.6	2.7	2.7	2.6	2.6	1.9
$\Delta\text{Xyl}$	0.6	0.4	0.3	0.3	0.2	0.1	0.2
$\Delta\text{Xylred(CHO)}$	1.1	1.0	1.3	1.0	0.8	0.5	0.6
Xyla(Py) + Xyl $\beta$ (Py)	1.4	1.3	0.6	0.5	0.3	0.2	0.2
MGA-(Xyl3Ac)	2.2	2.2	2.5	2.7	2.6	2.5	1.9
MGA-(Xyl)	1.1	1.2	0.8	0.9	0.9	0.7	0.7
MGA $^{\ominus}$ -(Xyl)	1.0	0.8	0.3	0.3	0.2	0.2	0.6
Degree of acetylation	4.1	4.8	5.1	5.2	5.2	5.5	4.5

Abbreviation: PPS, pentosan polysulfate.



**Fig. 3** Representative profiles of ITC titration at pH 7.2 of S1-RBD domain with fractions: (A) Fr-1.0 M, (B) Fr-1.2 M, and (C) Fr-1.4 M PPS in 20 mM HEPES buffer and 200 mM of salt. The upper panels show the raw data (heat pulse for every injection). The bottom panels represent integrated areas per mole of injected ligand as a function of molar ratio. The *solid line* is the best fit to the experimental data using a single-site binding model. ITC, isothermal titration calorimetry.

### ITC Determination of SARS-CoV-2 S1-RBD Binding to PPS

ITC is a sensitive technique for detecting biomolecular interactions by measuring the heat absorbed or released upon binding. ITC does not require immobilization or labeling of the partners and can be performed in solution, thereby measuring the affinity of binding molecules in their native state. In addition, ITC experiments provide not only the parameters relating to binding, such as binding constant ( $K_D$ ) and stoichiometry ( $N$ ), but also the enthalpy and entropy contributions of that binding ( $\Delta H$ ,  $\Delta S$ ) providing information concerning the nature and magnitude of the forces driving the binding. To evaluate the possible correlation between the binding affinity and the PPS chain length, ITC experiments were performed to address the interaction between the S1-RBD and PPS fractions with different average chain lengths. ITC experiments were first performed in PBS that mimics the pH, osmolarity, and ion concentration of human fluids. The ITC profiles of S1-RBD titrated with PPS and its fractions were fitted using the two binding-site models, involving two independents rather than sequential binding sites corresponding to a strong primary binding site and a nonspecific, secondary binding site (**Supplementary Table S2**, available in the online version). To minimize nonspecific binding, we performed the experiments increasing the salt concentration. At higher ionic strength (500 mM), the added salt led to full screening of the electrostatic interaction between PPS chains and S1-RBD with no evident heat changes in the ITC profiles. Furthermore, an increase of the salt concentration from 140 to 200 mM resulted in non-reproducible ITC titrations, despite the protein sample and

experimental conditions remaining unchanged during repeated measurements. We therefore changed the buffer solution from PBS to HEPES, which is another widely used buffer in biological studies, suitable for ITC experiments owing to its low ionization enthalpy. The state and conformational stability of the protein in HEPES buffer were further confirmed by DLS measurements and CD spectroscopy (**Supplementary Fig. S3**, available in the online version).

ITC thermograms resulting from the titration of S1-RBD in HEPES buffer using the same PPS fractions that were employed in the *in vitro* antiviral activity measurements are shown in **Fig. 3**. The ITC profiles showed exothermic heat of binding that could be fitted using a one-site binding site model (**Table 3**). The binding affinity was found to increase with the increasing length of ligand, as the apparent dissociation constant decreased as ligand molecular weight increased (from a  $K_D$  of  $8.410^{-7}$  to  $7.42 \times 10^{-8}$  M). For all fractions,  $N$  values were in the range of 0.18 to 0.24, indicating that four to five molecules of S1-RBD were bound to a single molecule of PPS. A similar binding stoichiometry had already been observed for PF4 and FGF1, which form multi-component complexes in the presence of heparin.<sup>29,30</sup> It can be hypothesized that one PPS chain is sandwiched between two dimers of S1-RBD by the negative charges present on both sides of the oligosaccharide. However, further experiments are necessary to confirm this hypothesis.

The binding to the S1-RBD resulted in negative binding free energy that became slightly more favorable at increasing ligand molecular weights (−8.29 to −9.73 kcal/mol). All interactions had both favorable enthalpy (−0.96 to −5.78 kcal/mol) and entropy (−3.15 to −7.72 kcal/mol) terms. The

**Table 3** Thermodynamic parameters obtained from ITC titrations of PPS fractions into S1-RBD domain using a single-site binding model

	MW (KDa)	N (sites)	$K_D$ (M)	$\Delta H$ (kcal/mol)	$\Delta G$ (kcal/mol)	$-T\Delta S$ (kcal/mol)
PPS <sup>a</sup>	5.7	0.20 ± 0.01	$6.13 \times 10^{-7} \pm 3.96 \times 10^{-7}$	$-2.20 \pm 1.45$	-8.48	-6.28
Fr-1.0M	3.7	0.24 ± 0.05	$8.41 \times 10^{-7} \pm 5.36 \times 10^{-7}$	$-0.97 \pm 0.34$	-8.29	-7.31
Fr-1.1M	5.3	0.18 ± 0.11	$4.33 \times 10^{-7} \pm 3.48 \times 10^{-7}$	$-0.96 \pm 0.74$	-8.68	-7.72
Fr-1.2M	7.0	0.24 ± 0.05	$2.85 \times 10^{-7} \pm 1.58 \times 10^{-7}$	$-5.78 \pm 1.80$	-8.93	-3.15
Fr-1.3M	9.2	0.23 ± 0.04	$1.84 \times 10^{-7} \pm 1.00 \times 10^{-7}$	$-4.02 \pm 0.99$	-9.19	-5.17
Fr-1.4M	11.8	0.22 ± 0.04	$1.61 \times 10^{-7} \pm 1.07 \times 10^{-7}$	$-4.64 \pm 1.34$	-9.27	-4.63
Fr-2.0M	17.3	0.22 ± 0.02	$7.42 \times 10^{-8} \pm 3.69 \times 10^{-8}$	$-5.24 \pm 0.70$	-9.73	-4.49

Abbreviations: ITC, isothermal titration calorimetry; PPS, pentosan polysulfate.

Note: Titration was performed in 20 mM HEPES buffer pH 7.4 and 200 mM NaCl (140 mM NaCl).

<sup>a</sup>140 mM NaCl.

negative enthalpic contribution to binding was mainly due to the formation of strong ionic interactions, in addition to hydrogen bonds and van der Waals interactions between the side chains of basic residues on the S1-RBD surface and the sulfate groups of the ligand. The favorable entropic contribution was presumably due to the higher release of water molecules to bulk upon ligand and target interaction.

In contrast with PPS fractions, titration experiments performed using the PPS mixture as a ligand showed no interactions at 200 mM NaCl, consistent with a low affinity of binding ( $K_D$  in the mM range), which could not be detected with ITC measurements (► **Supplementary Fig. S4**, available in the online version). However, calorimetric titrations performed decreasing the salt concentration at 140 mM resulted in a binding isotherm with a  $K_D$  of  $6.13 \times 10^{-7} \pm 3.96 \times 10^{-7}$  M and with binding that was enthalpically ( $\Delta H = -2.20$  kcal/mol) as well as entropically ( $-T\Delta S = -6.28$  kcal/mol) driven. The resulting binding stoichiometry was similar to that found for the fractions, where 4–5 S1-RBD molecules bind one molecule of PPS. To confirm that high salt concentrations screened any electrostatic interactions between PPS and S1-RBD, an ITC titration was performed, lowering the salt concentration to 60 mM (► **Supplementary Fig. S4**, available in the online version). The fitted data yielded a lower dissociation constant ( $K_D$ :  $1.64 \times 10^{-7} \pm 0.47 \times 10^{-7}$  M), suggesting that electrostatic interactions contribute significantly to the affinity between the PPS and the S1-RBD domain.

### Structural Characterization of SARS-CoV-2 S1-RBD upon Binding to PPS

Since no significant changes were observed in the hydrodynamic radius of the S1-RBD in complex with the PPS chains, we investigated whether alterations in the S1-RBD structure accompany the binding. Far-UV CD spectroscopy that is sensitive to conformational changes in proteins upon ligand binding was employed. Specifically, the CD signal in the far-UV (200–250 nm) provides information concerning changes in the proportions of secondary structural elements ( $\alpha$ -helices,  $\beta$ -sheet, and unstructured regions) that could take place following ligand binding. The far-UV CD spectra ac-

quired on S1-RBD at increasing ligand concentration reported only slight changes of secondary structure, without highlighting any trend related to increased concentrations of PPS or its fractions (► **Table 4**). In agreement with the DLS data, no increase in antiparallel  $\beta$ -sheet content was measured, which can indicate aggregation, nor was an increase in the level of signal amplification required (which would have been indicative of scattering arising from aggregation). These results suggest that the various ligands tested induce broadly similar conformations in the protein and are consistent with the interpretation that no significant aggregation was associated with the binding.

### PPS Binding-Site Analysis

The determination of the possible contacts between a 2,3-disulfated polyxyylan oligosaccharide and the S1-RBD of the SARS-CoV-2 was performed by molecular docking simulation, in which the hexasaccharide 2,3,4-trisulfo-Xyl- $\beta$ (1-4)-[2,3-disulfo-Xyl]<sub>5</sub>-OH was docked onto the convex surface of the S1-RBD (receptor). The conformation of 2,3-disulfo-xylan residues was set in the <sup>1</sup>C<sub>4</sub> conformation as suggested by <sup>3</sup>J<sub>H-H</sub> couplings, nuclear Overhauser effect contacts, and molecular modeling analysis (► **Supplementary Fig. S5**, available in the online version). The xylohexasaccharide model was built in two limit conformations, setting all the xylose (Xyl) residues in <sup>1</sup>C<sub>4</sub> and <sup>4</sup>C<sub>1</sub> chair forms. After energy minimization, the xylohexasaccharide with residues in <sup>1</sup>C<sub>4</sub> showed the lowest potential energy ( $-5,318.81$  kJ/mol) compared with the <sup>4</sup>C<sub>1</sub> conformation ( $-5,281.10$  kJ/mol). Interestingly, the <sup>1</sup>C<sub>4</sub> xylohexasaccharide allows greater distances between the two sulfate groups located at 2-O- and 3-O- of each Xyl residues (► **Supplementary Fig. S5**, available in the online version). The observed inversion of conformation of the xylose pyranoside ring from <sup>4</sup>C<sub>1</sub> to <sup>1</sup>C<sub>4</sub>, resulting from repulsion between the negatively charged sulfate groups, has also been observed for the internal chain residues of 2–3-disulfo-Xylo-oligosaccharides<sup>31</sup> and the glucuronic acid residue of chondroitin, following full chemical O-sulfation.<sup>32</sup>

The targeted site on the S1-RBD was identified by the series of amino acids that are characterized by

**Table 4** Conformational changes in S1-RBD upon addition of PPS or PPS fractions, determined by far UV-CD

	P:L ratio	Helix	Antiparallel	Parallel	Turn	Others	NRMSD
PPS	0.0	4.3	35	0.5	12.1	48.0	0.044
	0.2	4.5	37.7	0	12	45.9	0.026
	0.3	4.3	38	0	13.5	44.2	0.025
	0.9	7.3	34.5	2.8	12.3	43.2	0.020
Fr-1.0M	0.0	4.5	35	2.5	12.5	45.6	0.033
	0.2	4.4	35.9	3.1	10.3	46.2	0.036
	0.3	4.1	36.4	0	13.4	46.1	0.026
	0.9	7	36.7	0	13.2	43.2	0.022
Fr-1.2M	0.0	6.4	37.7	0	15.2	40.7	0.044
	0.2	3.8	39.3	0.3	9.5	47.0	0.039
	0.3	8.5	37.5	0.6	9.3	44.1	0.035
	0.9	3.8	39.4	0	14	42.8	0.039
Fr-1.4M	0.0	7.5	37.6	2.3	10.6	42.2	0.034
	0.2	4.7	34.9	2.7	12.1	45.6	0.032
	0.3	4.1	35.4	1.6	14.1	44.7	0.026
	0.9	4.1	35	3.1	11.4	46.3	0.034

Abbreviations: NRMSD, normalized root-mean-square deviation; PPS, pentosan polysulfate; UV-CD, ultraviolet circular dichroism.


predominantly positively charged side chains: R346, N354, R355, R357, K444, R466, which remain accessible from the solvent when the S1-RBD is in the “up” conformation on the trimeric S protein. This region has been identified previously as the preferred molecular recognition site toward glycosaminoglycans.<sup>6</sup> The docking simulation was set up centering the grid box on the C<sub>α</sub> of K356 and taking care to leave suitable space for the ligand to be adjusted on the surface of the S1-RBD, considering all possible relative orientations between the ligand and the receptor that were explored in the automatic search procedure. The docked solutions were clustered (tolerance < 2.0 Å), and the clusters ranked by the predicted binding energy (Auto-dock 4.2 score function). Clusters of docking solutions were then selected considering the binding energy and the population of the clusters. Analysis of the docking solutions suggested weak specificity in the molecular recognition between the hexasaccharide and the S1-RBD of SARS-CoV-2. In fact, 22 clusters of poses (populated by from 1 to 6 poses) presented binding energies between -3.5 and -1 kcal/mol. Interestingly, the lowest binding energy structures (-3.5 kcal/mol) correspond to two different clusters of docking poses. These two sets of docking solutions are reported in ►Fig. 4, showing contacts between the amino acids of the site I identified on the S1-RBD and the sulfate groups of the hexasaccharide. These solutions are located at the edge of the β-sheet that includes the site I sequence (N354, R355, K356, R357), and correspond to the shallow groove delimited by the short helix (C336 and R346) from one side and the loop (P463-S469) to the other side (►Fig. 4). In this case both docking solutions present

comparable contact distances (2.7–4.0 Å) between the residues of the site I core (N354, R355, K356, R357) and the nearest sulfate groups of the hexasaccharide.

**SARS-CoV-2 Viral Plaque-Forming Assays and S1-RBD Binding**

It has been established that the anionic, linear cell surface polysaccharide, HS, is an endogenous receptor for several pathogenic viruses,<sup>8,9,11</sup> including SARS-CoV-2<sup>6,7</sup> and that heparin, a closely related, negatively charged polysaccharide with structural similarities to HS, can inhibit this interaction.<sup>6,7,10</sup> It has been observed for several protein interactions that other sulfated polysaccharides, including those obtained by chemical sulfation of naturally occurring materials, can emulate heparin and HS, to induce biological effects.<sup>33,34</sup> The possibility that PPS, which is itself a semi-synthetic product made by the chemical sulfation of a naturally occurring plant xylan and may possess similar inhibitory activities was therefore investigated.

PPS is an established and approved treatment for cystitis, which can be administered orally, and shows very low toxicity even at high dose (300 mg/day).<sup>24</sup> It is also reported to exhibit potentially advantageous anti-inflammatory properties.<sup>20</sup> This alternative potential inhibitor was therefore explored using an established cell-based model of SARS CoV-2 virus invasion and its potency was found to be similar to UFH (►Fig. 5A). It was found that PPS was able to inhibit viral invasion in experiments involving all three forms of addition; PPS added to cells (cell), to virus (virus), and when added to both before being mixed (virus + cell) as shown in ►Fig. 5A. All three independent experimental approaches highlighted



**Fig. 4** Xylohexasaccharide 2,3,4-trisulfo-Xyl- $\beta$ (1-4)-[2,3-disulfo-Xyl]<sup>5</sup>-OH docked on the S1-RBD of the SARS-Cov-2. The representations correspond to the two preferred docking solutions (A and B panels), decomposed in terms of binding energy, but showing different molecular recognition patterns (RMSD > 2.0 Å). Distance between the sulfate groups of the ligand and the side chains of selected amino acids are underlined by dashed lines and reported in Å. The S1-RBD is shown in white ribbon. The amino acids that belong to the site I of the S1-RBD<sup>16</sup>, are drawn in green, blue, and red tubes, represent carbon, nitrogen, and oxygen atoms, respectively. The concave ACE2-binding surface is oriented to the top of the image. The approximate positions of C336, P463, and S469 are underlined to help the reader to locate the helix (C336-R346) and the loop (P463-S469) delimiting the recognition for linear poly-sulfated glycans (see the text). RMSD, root-mean-square deviation.

an inhibitory capacity of PPS at least equal to, if not greater than, that of heparin (UFH) on a weight per volume basis.

The PPS fractions showed some variation in activity. When compared on a molar basis, a direct  $M_w$  dependence was observed, the higher molecular weight fraction (Fr-1.4M;  $M_w$  11.8 kDa) being the most active (**Fig. 5C**). However, attributing this with confidence to any particular structural difference is more difficult because the fractions have broadly similar compositions (**Table 2**). The inhibitory efficacy of PPS, UFH, and LMWH (enoxaparin) were also compared on a weight per volume basis (**Fig. 5D**). It is clear that PPS is an inhibitor as effective as UFH, when added to cells, on a weight per volume basis (achieving ca. 60% inhibition compared with the no inhibitor control), and is more potent than LMWH (which achieved ca. 25% inhibition (**Fig. 5D**), which has a closely comparable molecular weight (**Table 1**). Additionally, both PPS and its fractions inhibited viral infection in a dose-dependent manner (in the range 12.5–200  $\mu\text{g}/\text{mL}$ ) (**Fig. 5B, C**).

#### PPS and Fractions Exhibit Reduced Anticoagulant Activity Compared with Heparin


A key advantage of PPS is that it exhibits reduced anticoagulant potential (**Supplementary Table S3**, available in the online version) which is an important consideration, since high doses may be required in any use as an antiviral agent. Moreover, PPS is less likely to induce bleeding complications. The conventional approach to avoiding the most serious side effects of prolonged treatment with heparin, such as heparin-HIT, is to employ LMWH, and a similar strategy could be envisaged in attempting to inhibit SARS-CoV-2.

The anticoagulant activity of PPS and derived fractions was measured as aPTT activity in comparison with heparin and enoxaparin. As expected, a steady increase of anticoagulation activity with higher molecular weight PPS fractions was observed in the aPTT assay, but always clearly less than heparin.

#### Discussion and Conclusion

Almost 2 years after the onset of the SARS-CoV-2 pandemic, most countries are still to reach the high levels of vaccination coverage that is necessary to achieve herd immunity. This is compounded by the gradual loss of immunity among those who have already been vaccinated or those who have recovered from an earlier infection, and this gradual loss of protection has also been linked to frailty, obesity, and deprivation.<sup>35</sup> The only therapeutic options available currently to treat the early symptoms of coronavirus are injectable antiviral drugs and it was only at the beginning of November 2021 that the first oral antiviral drug (molnupiravir) was approved for use in the United Kingdom. There is, therefore, an on-going need to develop additional treatments.

While heparins, the established family of anticoagulant polysaccharides, have shown promise in clinical use,<sup>36,37</sup> reservations remain concerning their direct use as antiviral treatments around potential bleeding complications and the onset of HIT as a side effect; both of which are associated with high dose and prolonged use. Consequently, alternative agents, which maintain desirable antiviral properties, while offering reduced anticoagulant and HIT risk, are sought.



**Fig. 5** PPS inhibition of SARS-CoV-2 infection. (A) Vero cells were treated with PPS and heparin (both at 100 µg/mL) prior to infection with 50 PFU of SARS-CoV-2 or virus-containing supernatant (50 PFU) was treated with the PPS or heparin. In addition, both cells and virus were treated with PPS or heparin as described in the Methods and Materials sections. (B) Dose response when Vero cells were treated with PPS serial dilution prior to infection with 50 PFU of SARS-CoV-2, virus-containing supernatant. (C) Dose response of PPS and PPS fraction-mediated inhibition of SARS-CoV-2 viral invasion of Vero cells. 50 PFU were treated with the PPS serial dilution, both cells and virus were treated with PPS. (D) The PPS-mediated inhibition of SARS-CoV-2 viral invasion of Vero cells (100 µg/mL) compared with heparin and LMWH. One-way ANOVA with Bonferroni correction was used to determine the *p*-values. Nil represents no treatment. ANOVA, analysis of variance; LMWH, low-molecular-weight heparin; PPS, pentosan polysulfate.

PPS, which is already in use for the relief of bladder pain and discomfort associated with interstitial cystitis, has been shown here to possess antiviral properties comparable to those of UFH and stronger than those of LMWHs. In contrast to heparin, the lower anticoagulant (aPTT) potency of PPS (10-fold lower compared with heparin) and lack of anti-Xa activity could allow its administration at higher doses thereby enabling its antiviral properties to be exploited.<sup>38,39</sup> The oligosaccharide fractions of PPS maintain the antiviral properties of the parent intact polysaccharide and this may provide a way of avoiding potential side effects analogous to HIT, which depend on the formation of immunogenic complexes between platelet factor 4 and HS oligosaccharides of ca. 9 kDa or larger.<sup>40</sup>

Both PPS and its fractions bind the S1-RBD efficiently, with  $K_D$  values in the µM to nM range, with similar energy changes, and both involve interactions that are driven, as expected, primarily by charge-charge interactions (► **Table 3**). It is not known whether the detailed interactions of PPS and its fractions with the protein are identical to those of heparin, but docking experiments suggest that the interactions of both heparin and PPS with S1-RBD occur between the sulfate groups of the xylohexasaccharide and the site I sequence of S1-RBD (N354, R355, K356, R357).<sup>6,7</sup> An interesting observation is the change from the normally predominant <sup>4</sup>C<sub>1</sub> chair form of unsulfated pentosan and xylans<sup>41</sup> to the <sup>1</sup>C<sub>4</sub> conformation for the polysulfated xylose residues. This is presumably the result of repulsion between the charged sulfate groups in positions 2 and 3, favoring the lower energy <sup>1</sup>C<sub>4</sub> conformation and a greater distance between the two sulfate groups (► **Supplementary Fig. S5**, available in the online version).

The far-UV CD spectra of the S1-RBD alone and the protein in the presence of PPS, while closely similar, are, nevertheless, not identical (► **Table 4**). While this is broadly consistent with there being no major change of secondary structure, minor changes in the protein secondary structure cannot be excluded. The origin of such differences may reside in subtle distinction between the modes of binding of these two polyanions.

It has been noted that, owing largely to our lack of precise understanding at the molecular level of many viral invasion mechanisms, it is probable that most current antiviral strategies are not optimised<sup>42</sup> and this is certainly true for the inhibition of invasion by SARS-CoV-2. It is also noteworthy that both SARS-CoV (CoV-1) and the present SARS CoV-2 have been found to be susceptible to inhibition by anionic polysaccharides,<sup>6,8</sup> and this class of compounds warrants more extensive investigation for the inhibition of viral invasion. Furthermore, PPS and fractions derived from it exhibit reduced anticoagulant activity for the inhibition of invasion of susceptible cells by SARS CoV-2 and merit further investigation for potential use as a treatment. While maintaining a better level of inhibitory potential on a weight per volume basis than LMWH and similar to that of UFH, PPS exhibits lower anticoagulant activity. Therefore, PPS should be less prone to bleeding complications at high doses and, by virtue of its distinct structure and the maintenance of antiviral activity in fractions derived from it, offers an alternative that is likely to be free of HIT or analogous side effects. Concentrations of PPS effective for antiviral activity can be reached at the level of the luminal surface of the first respiratory tract by using nebulization as a route of administration. This strategy has already been tested for heparin.<sup>43</sup> The starting material is derived from pentosan, a plant-derived polysaccharide xylan with a well-defined repeating structure<sup>19</sup> and, even following a chemical sulfation step, it remains highly homogeneous, making it easier to ensure both consistency and to avoid contamination, two problems that have dogged heparin production in recent years.<sup>44,45</sup>

### What is known about this topic?

- The pandemic COVID-19 disease is of global significance and an international health emergency.
- Additional treatments to vaccines are required.
- Heparin inhibits cellular invasion of SARS-CoV-2 coronavirus in live virus assays.
- Heparin efficacy appears to depend largely in its interactions with the spike protein of SARS-CoV-2.
- The occurrence of bleeding complications and the documented risk of heparin-induced thrombocytopenia (HIT) after prolonged exposure both limit the use of heparin in patients having high incidence of VTE, particularly for high-dose administration.
- Several studies have suggested that other sulfated molecules and highly charged polyelectrolytes also inhibit cellular invasion of SARS-CoV-2 coronavirus in live virus assays.
- Pentosan polysulfate, a plant-derived xylan that has been approved for the treatment of bladder pain and discomfort in interstitial cystitis, could represent an alternative to heparin.

### What does this paper add?

- Pentosan polysulfate has been shown to possess antiviral properties comparable to those of UFH and stronger than those of LMWH.
- The lower anticoagulant potency of PPS and lack of anti-Xa activity could allow its administration at higher doses thereby enabling its antiviral properties to be exploited.
- Both PPS and its fractions bind the S1-RBD efficiently, with  $K_D$  values in the  $\mu\text{M}$  to nM range,
- PPS polysulfated xylose residues change their conformation from the normally predominant  ${}^4\text{C}_1$  chair form of unsulfated pentosan and xylans<sup>39</sup> to the  ${}^1\text{C}_4$  conformation.
- Like heparin, the interaction of PPS with S1-RBD occurs between the sulfate groups of the xylohexasaccharide and the site I sequence of S1-RBD.
- The starting material is derived from a plant-derived polysaccharide xylan with a well-defined repeating structure and, even following a chemical sulfation step, it remains highly homogeneous, making it easier to ensure both consistency and to avoid contamination.

**Funding**  
None.

**Conflict of Interest**  
None declared.

### References

- 1 Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol* 2021;19(03):141–154
- 2 Beigel JH, Tomashek KM, Dodd LE, et al; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 - final report. *N Engl J Med* 2020;383(19):1813–1826
- 3 Koirala J, Gyanwali P, Gerzoff RB, et al; Nepal COVID-19 Clinical Study Collaborators. Experience of treating COVID-19 with Remdesivir and convalescent plasma in a resource-limited setting: a prospective, observational study. *Open Forum Infect Dis* 2021;8(08):b391
- 4 Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. *J Biol Chem* 2021;297(01):100770
- 5 Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. *Nat Struct Mol Biol* 2021;28(09):740–746
- 6 Mycroft-West CJ, Su D, Pagani I, et al. Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the spike S1 receptor-binding domain with heparin. *Thromb Haemost* 2020;120(12):1700–1715
- 7 Clausen TM, Sandoval DR, Spliid CB, et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. *Cell* 2020;183(04):1043–1057
- 8 Vicenzi E, Canducci F, Pinna D, et al. Coronaviridae and SARS-associated coronavirus strain HSR1. *Emerg Infect Dis* 2004;10(03):413–418
- 9 Nahmias AJ, Kibrick S. Inhibitory effect of heparin on herpes simplex virus. *J Bacteriol* 1964;87(05):1060–1066
- 10 Skidmore MA, Kajaste-Rudnitski A, Wells NM, et al. Inhibition of influenza H5N1 invasion by modified heparin derivatives. *Med-ChemComm* 2015;6:640–646
- 11 Germi R, Crance JM, Garin D, et al. Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. *Virology* 2002;292(01):162–168
- 12 Ghezzi S, Cooper L, Rubio A, et al. Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells. *Antiviral Res* 2017;140:13–17
- 13 Tandon R, Sharp JS, Zhang F, et al. Effective inhibition of SARS-CoV-2 entry by heparin and enoxaparin derivatives. *J Virol* 2021;95(03):1–12
- 14 Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. *Semin Thromb Hemost* 2021;47(04):372–391
- 15 Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. *Blood Adv* 2021;5(03):872–888
- 16 Schuurs ZP, Hammond E, Elli S, et al. Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain. *Comput Struct Biotechnol J* 2021;19:2806–2818
- 17 Kwon PS, Oh H, Kwon SJ, et al. Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro. *Cell Discov* 2020;6(01):50
- 18 Nie C, Pouyan P, Lauster D, et al. Polysulfates block SARS-CoV-2 uptake through electrostatic interactions. *Angew Chem Int Ed Engl* 2021;60(29):15870–15878
- 19 Alekseeva A, Raman R, Eisele G, et al. In-depth structural characterization of pentosan polysulfate sodium complex drug using orthogonal analytical tools. *Carbohydr Polym* 2020;234:115913
- 20 Sanden C, Mori M, Jogdand P, et al. Broad Th2 neutralization and anti-inflammatory action of pentosan polysulfate sodium in experimental allergic rhinitis. *Immun Inflamm Dis* 2017;5(03):300–309

- 21 Fellstrom B, Bjorklund U, Danielson BG, et al. Pentosan polysulfate (ELMIRON®): pharmacokinetics and effects on the urinary inhibition of crystal growth. In: Vahlensieck W, Gassner G, eds. *Pathogenese und Klinik der Harnsteine*. Darmstadt:: Steinkopff-Verlag;; 1987:340–396
- 22 Simon M, McClanahan RH, Shah JF, Repko T, Modi NB. Metabolism of [<sup>3</sup>H]pentosan polysulfate sodium (PPS) in healthy human volunteers. *Xenobiotica* 2005;35(08):775–784
- 23 Erickson DR, Sheykhnazari M, Bhavanandan VP. Molecular size affects urine excretion of pentosan polysulfate. *J Urol* 2006;175(3, Pt 1):1143–1147
- 24 Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR. Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study. *Urology* 1990;35(06):552–558
- 25 Bisio A, Mantegazza A, Vecchietti D, et al. Determination of the molecular weight of low-molecular-weight heparins by using high-pressure size exclusion chromatography on line with a triple detector array and conventional methods. *Molecules* 2015;20(03):5085–5098
- 26 Bertini S, Risi G, Guerrini M, Carrick K, Szajek AY, Mulloy B. Molecular weights of bovine and porcine heparin samples: comparison of chromatographic methods and results of a collaborative survey. *Molecules* 2017;22(07):1214
- 27 Guerrini M, Naggi A, Guglieri S, Santarsiero R, Torri G. Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. *Anal Biochem* 2005;337(01):35–47
- 28 Mauri L, Boccardi G, Torri G, et al. Qualification of HSQC methods for quantitative composition of heparin and low molecular weight heparins. *J Pharm Biomed Anal* 2017;136:92–105
- 29 Kreimann M, Brandt S, Krauel K, et al. Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. *Blood* 2014;124(15):2442–2449
- 30 Robinson CJ, Harmer NJ, Goodger SJ, Blundell TL, Gallagher JT. Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes. *J Biol Chem* 2005;280(51):42274–42282
- 31 Vo Y, Schwartz BD, Onagi H, et al. A rapid and mild sulfation strategy reveals conformational preferences in therapeutically relevant sulfated Xylooligosaccharides. *Chemistry* 2021;27(38):9830–9838
- 32 Maruyama T, Toida T, Imanari T, Yu G, Linhardt RJ. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. *Carbohydr Res* 1998;306(1-2):35–43
- 33 Uniewicz KA, Ori A, Xu R, et al. Differential scanning fluorimetry measurement of protein stability changes upon binding to glycosaminoglycans: a screening test for binding specificity. *Anal Chem* 2010;82(09):3796–3802
- 34 Lima MA, Hughes AJ, Veraldi N, et al. Antithrombin stabilisation by sulfated carbohydrate s correlates with anticoagulant activity. *MedChemComm* 2013;4(05):870–873
- 35 Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *Lancet Infect Dis* 2022;22(01):43–55
- 36 van Haren FMP, Page C, Laffey JG, et al. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. *Crit Care* 2020;24(01):454
- 37 Rentsch CT, Beckman JA, Tomlinson L, et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. *BMJ* 2021;372(311):n311
- 38 Soria C, Soria J, Ryckewaert JJ, Holmer E, Caen JP. Anticoagulant activities of a pentosane polysulphate: comparison with standard heparin and a fraction of low molecular weight heparin. *Thromb Res* 1980;19(4–5):455–463
- 39 Vinazzer H, Haas S, Stemberger A. Influence on the clotting mechanism of sodium pentosan polysulfate (SP54) in comparison to commercial beef lung sodium heparin. *Thromb Res* 1980;20(01):57–68
- 40 Stringer SE, Gallagher JT. Specific binding of the chemokine platelet factor 4 to heparan sulfate. *J Biol Chem* 1997;272(33):20508–20514
- 41 Berglund J, Angles d'Ortoli T, Vilaplana F, et al. A molecular dynamics study of the effect of glycosidic linkage type in the hemicellulose backbone on the molecular chain flexibility. *Plant J* 2016;88(01):56–70
- 42 Magden J, Kääriäinen L, Ahola T. Inhibitors of virus replication: recent developments and prospects. *Appl Microbiol Biotechnol* 2005;66(06):612–621
- 43 van Haren FMP, Laffey JG, Artigas A, et al; CHARTER Collaborative Research Group. Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID-19 Requiring invasive ventilation Meta-Trial (CHARTER-MT): protocol and statistical analysis plan for an investigator-initiated international meta-trial of prospective randomised clinical studies. *Br J Clin Pharmacol* 2022. Doi: 10.1111/bcp.15253
- 44 Ramacciotti E, Clark M, Sadeghi N, et al. Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications. *Clin Appl Thromb Hemost* 2011;17(02):126–135
- 45 Guerrini M, Zhang Z, Shriver Z, et al. Orthogonal analytical approaches to detect potential contaminants in heparin. *Proc Natl Acad Sci U S A* 2009;106(40):16956–16961